The pharmaceutical giant Novo Nordisk is navigating a complex landscape of commercial wins and growing analyst skepticism, a duality that encapsulates the company’s current position: a robust core business tempered by increasing doubts about its long-term trajectory. Recent developments, including a significant partnership with telehealth provider Hims & Hers and a downgrade from a leading financial analyst firm, highlight the challenges and opportunities facing the Danish drugmaker as it seeks to maintain its dominance in the rapidly evolving market for obesity and diabetes treatments.
The shifting dynamics surrounding Novo Nordisk underscore the delicate balance between capitalizing on current successes and preparing for future competition. The company’s blockbuster drugs, Ozempic and Wegovy, have revolutionized the treatment of type 2 diabetes and obesity, driving substantial revenue growth. However, the looming threat of generic competition, coupled with the emergence of rival therapies, is prompting analysts to reassess the company’s long-term prospects.
Novo Nordisk and Hims & Hers Reach Agreement, Ending Patent Dispute
Novo Nordisk has reached a settlement with Hims & Hers Health, Inc., resolving a patent dispute over compounded versions of its weight-loss drugs, Ozempic and Wegovy. The agreement, announced on March 11, 2026, establishes a collaborative partnership where Hims & Hers will offer FDA-approved Ozempic and Wegovy products on its platform at prices consistent with other telehealth providers. According to the Associated Press, this move effectively ends Hims & Hers’ practice of selling compounded versions of the drugs, which had sparked the legal battle.
The dispute originated from Hims & Hers’ attempt to offer a $49 copy of Novo Nordisk’s obesity pill, a venture quickly halted. In exchange for ending the legal challenge, Hims & Hers will cease promoting compounded GLP-1 medications. FDA Commissioner Marty Makary publicly welcomed the agreement. The market reacted favorably to the news, with Hims & Hers shares surging 41% and Novo Nordisk’s U.S.-listed shares rising approximately 3%. For Novo Nordisk, the deal eliminates a significant distribution headwind and mitigates legal risks.
Analyst Caution Grows Amid Competitive Pressures
Simultaneous with the Hims & Hers agreement, TD Cowen downgraded Novo Nordisk’s stock rating from “Buy” to “Hold” and reduced its price target from $45 to $42. Analyst Michael Nedelcovych cited concerns about increasing competition in the GLP-1 receptor agonist market and the eventual patent expiration of semaglutide, the active ingredient in both Ozempic and Wegovy. As reported by The Hill, Nedelcovych believes Novo Nordisk’s pipeline may not adequately address these future challenges.
TD Cowen isn’t alone in its cautious outlook. Goldman Sachs downgraded the stock to “Neutral” with a $41 price target in early March, and Deutsche Bank followed suit in late February with a “Hold” rating. As of March 11, 2026, Novo Nordisk’s stock is trading around $39.78, representing a more than 21% decline since the beginning of the year and a 53% drop from its 52-week high of $80.53.
CagriSema and the Competitive Landscape
A key concern for analysts centers on Novo Nordisk’s CagriSema, a potential successor to Wegovy. In an 84-week study, CagriSema demonstrated an average weight loss of 23%, slightly less than Eli Lilly’s tirzepatid, which achieved 25.5% weight loss. Importantly, CagriSema did not demonstrate non-inferiority to tirzepatid. Novo Nordisk has submitted CagriSema for FDA approval, with a decision expected by the end of 2026. A Phase 3 study with a higher dose of CagriSema is also planned for the second half of 2026.
Strong Q4 2025 Results Offset Concerns About 2026 Outlook
Despite the analyst concerns, Novo Nordisk reported strong financial results for the fourth quarter of 2025. The company’s total revenue reached 45.32 billion Danish kroner, exceeding estimates of 41.57 billion kroner. The obesity care segment experienced a 31% growth, generating 82.3 billion Danish kroner in revenue.
However, Novo Nordisk’s management has issued a cautious outlook for 2026, projecting a decline in organic sales growth of between 5% and 13% due to pricing pressures and increased competition. A recent study suggests that generic semaglutide could be available for less than $3 per month, posing a long-term threat to the company’s core products.
Novo Nordisk’s annual general meeting is scheduled for March 26, where shareholders will vote on the continuation of the company’s share repurchase program. Later in the year, the FDA’s decision on CagriSema will be a critical event for evaluating the company’s pipeline and future prospects.
Key Takeaways
- Strategic Partnership: Novo Nordisk has resolved its patent dispute with Hims & Hers through a collaboration to distribute FDA-approved Ozempic and Wegovy.
- Analyst Downgrades: Several financial firms have downgraded Novo Nordisk’s stock rating, citing concerns about competition and patent expiration.
- CagriSema Uncertainty: The performance of CagriSema, Novo Nordisk’s potential successor to Wegovy, remains a key factor in the company’s future.
- Mixed Financial Outlook: Whereas Q4 2025 results were strong, the company anticipates a decline in sales growth for 2026.
The coming months will be pivotal for Novo Nordisk as it navigates a challenging market landscape. The FDA’s decision on CagriSema and the company’s ability to address competitive pressures will be crucial in determining its long-term success. Investors and industry observers will be closely watching these developments as Novo Nordisk strives to maintain its position as a leader in the global obesity and diabetes care market. The next major checkpoint for investors will be the FDA decision regarding CagriSema later in 2026.
What are your thoughts on Novo Nordisk’s current situation? Share your insights and opinions in the comments below. Don’t forget to share this article with your network!